In our study, when comparing seizure outcomes in patients with oligodendrogliomas and with astrocytomas (based on the 2016 WHO update), the majority of patients with oligodendrogliomas were Engel Class IA in comparison with patients with astrocytoma IDH1/2 mutated or astrocytoma IDH1/2 wild type (81.82%, 68.89%, and 50%, respectively; p = 0.001). This evidence concerns the gene IDH1 and oligodendroglioma.